By Michael Dabaie

 

Bristol Myers Squibb said the European Commission approved Opdivo for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction cancer.

Bristol Myers said the approval is for patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.

The approval is based on results from the Phase 3 CheckMate -577 trial, which demonstrated that treatment with Opdivo following neoadjuvant chemoradiotherapy and complete surgical resection doubled the primary objective of disease-free survival compared with placebo, the company said.

In May, Opdivo received approval from the U.S. Food and Drug Administration for adjuvant treatment of completely resected esophageal or GEJ cancer.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

July 30, 2021 08:15 ET (12:15 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Bristol Myers Squibb Charts.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Bristol Myers Squibb Charts.